Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ethyl Chloride→

Ethyl Chloride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
75-00-3
Molecular formula
C2H5Cl
Molecular weight
64.514 g/mol
Drug class
Volatile topical vapocoolantlocal surface refrigerant analgesic
Mechanism of action
Rapid evaporation from the skin produces local cooling and transient reduction in cutaneous nerve conduction and pain perception. It acts physically as a refrigerant rather than through a receptor-mediated pharmacological pathway.
Indications / reported uses
  • Topical vapocoolant to provide brief local analgesia for injections, minor procedures, minor sports injuries and selected musculoskeletal pain applications, for products labelled for these uses.

Sources: https://www.accessdata.fda.gov/cdrh_docs/pdf/k984564.pdf · https://www.accessdata.fda.gov/cdrh_docs/pdf/k984522.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ethyl Chloride Environmental Risk Assessment (ERA) (the Ethyl Chloride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.